来曲唑联合唑来膦酸治疗绝经后乳腺癌骨转移临床观察被引量：1

下载PDF

导出

摘要目的观察来曲唑联合唑来膦酸治疗绝经后乳腺癌骨转移的疗效和毒副反应。方法 38例绝经后乳腺癌骨转移患者,口服来曲唑片2.5 mg/d,唑来膦酸4 mg加入0.9%氯化钠注射液100 ml,静滴(15 min以上),28 d为1个周期,3个周期后评价疗效并记录毒副反应。结果治疗后疼痛缓解率、骨转移灶改善率、活动改善有效率分别为86.84%、52.63%、73.68%,且患者的生活质量明显提高,毒副反应轻。结论来曲唑联合唑来膦酸治疗绝经后乳腺癌骨转移,安全、有效、耐受性好,是一良好的治疗方法。

作者陈素琼梁海田周锐

机构地区宁夏银川市第一人民医院肿瘤内科

出处《宁夏医学杂志》 CAS 2012年第9期923-924,共2页 Ningxia Medical Journal

关键词来曲唑唑来膦酸绝经后乳腺癌癌骨转移

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1Keating GM. Letrozole : a review of its use in the treatment of postm-eno - pausal women with hormone - responsive early breast cancer[J]. Drugs,2009,69(12) :1681 -1705. 被引量：1
2孙燕,石远凯主编..临床肿瘤内科手册第5版[M].北京:人民卫生出版社,2007:941.
3周际昌主编..实用肿瘤内科学[M].北京:人民卫生出版社,2003:818.
4Karmofsky DA,Burchenal JH, The clinical evaluation of chemother-apeutic agents in cancer. In:Me Load CM,ed. Evaluation of chemo-therapeutic agents [ M ]. New York: Columbia University Press,1949:191 -205. 被引量：1
5AkhtariM,Mensuri J,Newman KA,et a. 1 Biology of breast cancerbonemetastasis[ J]. Cancer Biol Ther,2008 ,7(1) :3 -9. 被引量：1
6王充顺,刘军,庞宏欣.乳腺癌内分泌治疗进展[J].现代肿瘤医学,2009,17(1):174-178. 被引量：20

二级参考文献33

1Hamilton A, piccart M. The third - generation non - steroidal aromatase inhibitors : a review of their clinical benefits in the second - line hormonal treatment of advanced breast cancer [J]. Anals of Oncology, 1999,10 (4) :377 - 384. 被引量：1
2Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer:an overview of the randomized trials [J].Lancet, 1998. 351 : 1451. 被引量：1
3江泽飞,宋三泰.乳腺癌的内分泌治疗[A].韩锐,孙燕.新世纪癌的化学预防与药物治疗[M].北京:人民军医出版社,2005:840. 被引量：2
4Lonning PE. Clinico - pharmacilogical aspects of different hormone treatment[J]. Eur J Cancer,2000,36( suppl 4) :81 -82. 被引量：1
5Howell A. Faslodex ( ICI 182780), an oestragen receptor downregulator [ J ]. Eur J Cancer,2000,36 ( suppl 4 ) : 87 - 88. 被引量：1
6Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women [ J ]. Oncologist ,2004,9 (2) : 126 - 136. 被引量：1
7Howell A, Cuzick J, Baum M, et al. Results of the ATAC ( Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years'adjuvant treatment for breast cancer[ J]. Lancet,2005, 365:60 -62. 被引量：1
8Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine - responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen : combined results of ABCSG Trial 8 and ARNO 95 Trial[J]. Lancet,2005,366 (9484) :455 - 462. 被引量：1
9Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer[ J]. N Engl J Med ,2005,353 (26) :2747 -2757. 被引量：1
10Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor- positive breast cancer :updated findings from NCIC CTG MA. 17 [J]. J Natl Cancer Inst,2005,97(17) :1262 -1271. 被引量：1